Navigation Links
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
Date:7/8/2008

20 mg/day and 30 mg/day), Concerta (36 mg/day and 54 mg/day) and placebo.

Primary efficacy was measured by the change from pre-dose in the Swanson, Kotkin, Agler, Mylnn, and Pelham (SKAMP) Rating Scale-Combined scores at two hours post-dose with Focalin XR 20 mg compared with Concerta 36 mg. The SKAMP rating scale is a standard assessment tool used in laboratory classroom clinical trials to evaluate attention and behavior.

Both doses of Focalin XR showed significantly greater improvement in SKAMP-Attention and -Deportment scores when compared with placebo at all measured time-points (30 minutes to 12 hours post-dose), except for 10-12 hours post-dose with 20 mg. Concerta 36 mg and 54 mg demonstrated efficacy at measured time-points 1-12 hours post-dose, but were no different to placebo at 30 minutes.

Because of the differences in release profiles, the investigators also studied overall efficacy during the 12 hour study period using an area under the curve analysis (AUC0-12) of the SKAMP combined scores. All doses of the active medication were significantly better than placebo. There was no difference between Focalin XR 20 mg and 30 mg when compared to both Concerta 36 mg and 54 mg, respectively, observed overall across the 12-hour day.

In general, both treatments were well tolerated and no patients discontinued or had a reduction in study drug dose due to an adverse event. A total of 81 children completed the study (three withdrew consent for reasons not related to study medications).

A previous head-to-head study comparing Focalin XR and Concerta published in the April 2008 Psychopharmacology Bulletin found similar efficacy and safety results to the present study.

About Focalin XR

Focalin XR (dexmethylphenidate HCl) extended-release capsules are indicated for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in adults, adolescents and children six years and older. Focalin XR is indicated as an integral
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
2. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
3. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , August 22, 2014 ... http://www.researchandmarkets.com/research/x34qgv/global_laboratory ) has announced the addition of ...  report to their offering.       ... an essential instrument for any modern science ... weighing of materials. It can be broadly ...
(Date:8/22/2014)... DUBLIN , August 22, 2014 /PRNewswire/ ... ) has announced the addition of the  ... to their offering.       (Logo: ... room with a sterile environment in a ... It is equipped with technically advanced equipment, ...
(Date:8/22/2014)... WASHINGTON , Aug. 22, 2014 ... Obamacare that modify the religious "accommodation" but still ... drugs that have an abortifacient effect, including Plan ... "week after pill"). The Obama Administration also announced ... religious, closely held, for-profit corporations. The ...
Breaking Medicine Technology:Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Liberty Institute: Government "Accommodation" Still Requires Employers To Facilitate Coverage Of Abortifacient Drugs 2
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Back-to-school time provides ... that fits into the family schedules, an expert suggests. ... child,s school year can also be the start of ... Richards, a professor of kinesiology at the University of ... release. With kids, extracurricular activities likely to build ...
(Date:8/22/2014)... 22, 2014 Dayton Children's Hospital broke ground ... part of a $141 million campus renewal. Renderings ... were unveiled to the public. , The new patient ... will create a campus that meets the needs of patients, ... care spaces will embody Dayton Children’s unique patient care mission ...
(Date:8/22/2014)... CLEVELAND Renal artery stenting to open blockages ... have historically been excluded from modern clinical trials, ... e-published in Catheterization and Cardiovascular Interventions ... Interventions (SCAI). , University Hospitals Case Medical Center,s ... and Professor of Medicine, Case Western Reserve University ...
(Date:8/22/2014)... Menstrual leaks risk stains and embarrassment, especially ... that there needed to be a better way to ... in design variations, the Safety Net optimizes protection during ... embarrassment and promotes peace of mind. The pad serves ... original design was submitted to the Fort Lauderdale office ...
(Date:8/22/2014)... who use reduced-nicotine cigarettes don,t smoke more to make ... a new study. This means they don,t inhale ... The month-long study included 72 adult smokers, aged ... emission levels of 1.2 milligrams (mg) each for one ... the next three weeks. In each of those ...
Breaking Medicine News(10 mins):Health News:With Kids in School, Parents Can Work Out 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2
... response to the growing,demand for solutions to ... United,States, a group of entrepreneurs has established ... consulting,firm with over 25 years experience in ... implement pharmaceutical care, and,"Inspire Pharmacists to Practice ...
... Quantify Competitive Treatment Landscape and Support Model-Based Drug ... ... 27 Pharsight,Corporation (Nasdaq: PHST ), a leading provider of ... that it has licensed its public-source Type II,Diabetes meta- database to ...
... Oxygen Community Praises Congressman for Formally Opposing Deep,Cuts ... March 26 Pacific Pulmonary,Services - Ukiah Center, ... and services to more than 200 patients in ... Thompson (CA-1st) to,meet with patients, physicians and technicians ...
... Actuaries Unveil Election 2008 Resources for Voters on ... The American Academy of,Actuaries said the most ... address the program,s long-term financing issues.,According to the ... income from payroll taxes, and Medicare must,rely also ...
... in 2008, -- IND filing for liquid formulation NGX-1998 expected in first half of ... ... under EMEA review for neuropathic pain ... Calif., March 26 NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused on developing ...
... Hillenbrand,Industries, Inc. (NYSE: HB ) (the "Company") announced ... in connection with its previously,announced cash tender offer to ... Notes due 2009 (CUSIP No. 431573AD6). The tender offer ... February 29, 2008 (the,"Offer to Purchase") and the related ...
Cached Medicine News:Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 2Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 3Health News:Pharsight Signs New Diabetes Meta-Database Customer 2Health News:Pharsight Signs New Diabetes Meta-Database Customer 3Health News:Ukiah Home Oxygen Therapy Patients and Physicians Meet with Congressman Mike Thompson to Share Benefits of Quality Home Oxygen Care 2Health News:Ukiah Home Oxygen Therapy Patients and Physicians Meet with Congressman Mike Thompson to Share Benefits of Quality Home Oxygen Care 3Health News:Medicare Trustees' Report Highlights Need for Reform 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 8Health News:Hillenbrand Industries, Inc. Announces Pricing of Its Pending 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces Pricing of Its Pending 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces Pricing of Its Pending 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: